🚨 JUST IN: $GOSS
Gossamer Bio submits NDA for seralutinib in PAH; FDA acceptance decision expected later 2026
#SEC #stocks #investing #GOSS #Regulatory
đź”— secwatch.observer

🚨 JUST IN: $GOSS
Gossamer Bio submits NDA for seralutinib in PAH; FDA acceptance decision expected later 2026
#SEC #stocks #investing #GOSS #Regulatory
đź”— secwatch.observer
#GOSS Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
#GOSS Gossamer Bio Announces 1-for-80 Reverse Stock Split